Gilead Sciences, Inc.

Gilead Sciences Inc on Friday notified the U.S. health regulator of its decision to voluntarily withdraw the use of its drug Zydelig for two types of cancer - follicular lymphoma and small lymphocytic leukemia.

Gilead Sciences Inc has notified the U.S. health regulator of its decision to voluntarily withdraw the use of its drug Zydelig for two types of cancer - follicular lymphoma and small lymphocytic leukemia. (Reporting by Leroy Leo in Bengaluru; Editing by Arun Koyyur)

The Russian government extended on Thursday its approval for drugmaker Pharmasyntez to produce a generic version of U.S. anti-COVID-19 drug remdesivir without a patent for one year, citing the need to protect its citizens.

Gilead Sciences Inc has said an Indian generic drugmaker's proposed version of the HIV drug Symtuza infringes its patents, in a lawsuit in Delaware federal court.

Gilead Sciences Inc on Thursday posted higher-than-expected third-quarter earnings on strong demand for its COVID-19 antiviral treatment, but said 2021 sales of its other drugs will fall short of earlier estimates.

Gilead Sciences Inc on Thursday posted higher-than-expected third-quarter earnings as strong demand for its COVID-19 antiviral treatment, Veklury, offset flagging sales of its HIV drugs.

(Corrects paragraph 1 and 2 to show one patent, not patents)

Gilead Sciences Inc escaped a $1.2 billion fine, after the Federal Circuit Court of Appeals on Thursday found the relevant parts of a Bristol Myers Squibb patent that Gilead's Yescarta cancer drug allegedly infringed were invalid.

Gilead Sciences Inc said on Monday it will require all its employees and contractors in the United States to become vaccinated against COVID-19.

Gilead Sciences said on Thursday it has become aware that tampered and counterfeit versions of its HIV treatments, Biktarvy and Descovy, are in circulation within U.S. drug distribution networks.

Eli Lilly and Co and partner Incyte Corp said on Tuesday additional results from a late-stage study showed their COVID-19 drug baricitinib reduced the risk of death in patients on mechanical ventilation.

Gilead Sciences Inc on Thursday posted a higher-than-expected second-quarter profit, helped by strong demand for its COVID-19 antiviral treatment, Veklury, but sales of its flagship HIV drugs lagged as the pandemic continued to limit visits to doctors.

Gilead Sciences Inc on Thursday posted higher second-quarter earnings, helped by strong sales of its COVID-19 antiviral treatment, Veklury, as well as hepatitis drugs.

The U.S. health regulator expanded the emergency use authorization for Eli Lilly's COVID-19 drug baricitinib, saying it could now be used without taking Gilead's drug remdesivir along with it, Lilly said on Thursday.

BioNTech said it was acquiring a production site and a research and development platform from a subsidiary of U.S. biotech company Gilead to expand its footprint in north America and in novel cancer treatments.

Federal authorities have seized at U.S. airports unauthorized versions of the COVID-19 treatment remdesivir destined for distribution in Mexico, the Wall Street Journal reported on Wednesday.

Gilead Sciences Inc said an analysis showed its antiviral remdesivir reduced mortality rates in hospitalized patients with COVID-19 and increased the likelihood of being discharged by day 28 after a five-day course of the treatment.

Russia's Supreme Court on Thursday rejected a lawsuit from U.S. company Gilead Sciences that challenged a Russian government decision to let a Russian firm develop and market the anti-COVID-19 drug remdesivir without Gilead's consent.

Russia's Supreme Court on Thursday rejected a lawsuit from U.S. company Gilead Sciences challenging the Russian government's decision last year to let a Russian pharmaceutical firm develop the COVID-19 drug remdesivir without Gilead's consent.